Search results
Showing 31 to 45 of 173 results for leukaemia
Ibrutinib with rituximab for untreated chronic lymphocytic leukaemia (terminated appraisal) (TA703)
NICE is unable to make a recommendation on ibrutinib (Imbruvica) with rituximab for untreated chronic lymphocytic leukaemia because Janssen did not provide an evidence submission.
Show all sections
Sections for TA703
Idelalisib with ofatumumab for treating chronic lymphocytic leukaemia (terminated appraisal) (TA469)
NICE is unable to make a recommendation about the use in the NHS of idelalisib with ofatumumab for treating chronic lymphocytic leukaemia because no evidence submission was received from Gilead Sciences.
Show all sections
Sections for TA469
Guidance on the use of imatinib for chronic myeloid leukaemia (TA70)
Evidence-based recommendations on imatinib for people with chronic myeloid leukaemia.
Pirtobrutinib for untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6397]
In development Reference number: GID-TA11501 Expected publication date: 24 February 2027
Evidence-based recommendations on ibrutinib (Imbruvica) for treating chronic lymphocytic leukaemia in adults.
NICE is unable to make a recommendation on dasatinib (Sprycel) for Philadelphia-chromosome-positive acute lymphoblastic leukaemia in children and adults because Bristol Myers Squibb did not provide an evidence submission.
Show all sections
Sections for TA714
Evidence-based recommendations on tisagenlecleucel (Kymriah) for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25 years and under.
Zanubrutinib for untreated chronic lymphocytic leukaemia [ID5079]
In development Reference number: GID-TA10966 Expected publication date: TBC
Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors (TA813)
Evidence-based recommendations on asciminib (Scemblix) for chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors.
NICE is unable to make a recommendation on blinatumomab (Blincyto) for previously treated Philadelphia-chromosome-positive acute lymphoblastic leukaemia in adults because Amgen UK did not provide an evidence submission.
Show all sections
Sections for TA686
NICE is unable to make a recommendation on decitabine–cedazuridine (Inaqovi) for untreated acute myeloid leukaemia in adults when intensive chemotherapy is unsuitable. This is because Otsuka Pharmaceuticals (UK) did not provide an evidence submission. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA932
NICE is unable to make a recommendation on ibrutinib (Imbruvica) with obinutuzumab for untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma in adults because Janssen did not provide an evidence submission.
Show all sections
Sections for TA702